An in vivo study in one ovarian cancer PDX model revealed that the combination of crizotinib (a c-Met inhibitor) and gedatolisib (a dual PI3K-mTOR inhibitor) exerted a more superior antitumor activity than single agent, while crizotinib alone presented no antitumor activity, and gedatolisib alone only displayed some marginal activity, suggesting that crizotinib promoted the activity of gedatolisib in treating ovarian cancer 73. The gene discussed is MTOR; the disease is ovarian cancer.